Caliber Wealth Management LLC KS Acquires Shares of 20,676 Johnson & Johnson (NYSE:JNJ)

Key Points

• Caliber Wealth Management LLC KS invested approximately $3.43 million in Johnson & Johnson by acquiring 20,676 shares in the first quarter.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding analysts' expectations of $2.68, and had revenue of $23.74 billion for the quarter.
• The company declared a quarterly dividend of $1.30 per share, representing a 3.07% dividend yield on an annualized basis, with a payout ratio of 55.61%.

Caliber Wealth Management LLC KS acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,676 shares of the company's stock, valued at approximately $3,429,000.

Several other hedge funds also recently made changes to their positions in JNJ. MBA Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares in the last quarter. Nabity Jensen Investment Management Inc grew its position in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company's stock valued at $2,151,000 after acquiring an additional 69 shares in the last quarter. Finally, Almanack Investment Partners LLC. lifted its position in Johnson & Johnson by 1.1% during the 1st quarter. Almanack Investment Partners LLC. now owns 6,633 shares of the company's stock worth $1,100,000 after acquiring an additional 71 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $2.39 during midday trading on Tuesday, reaching $168.61. The stock had a trading volume of 3,138,889 shares, compared to its average volume of 9,050,790. The firm has a 50 day simple moving average of $156.36 and a 200-day simple moving average of $156.14. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market cap of $405.69 billion, a PE ratio of 18.04, a P/E/G ratio of 2.14 and a beta of 0.41. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. The company's quarterly revenue was up 5.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.08%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. UBS Group upped their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.